Skip to main content

Advertisement

SpringerLink
Log in

Favorable HLA Polymorphisms are Associated with Lower Molecular Relapse after Tyrosine Kinase Discontinuation in Patients with Chronic Myeloid Leukemia

  • Correspondence
  • Published:
Indian Journal of Hematology and Blood Transfusion Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kimura S, Imagawa J, Murai K et al (2020) Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol 7:e218–e225

    Article  Google Scholar 

  2. Mahon F-X, Réa D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029–1035

    Article  CAS  Google Scholar 

  3. Saussele S, Richter J, Guilhot J et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747–757

    Article  CAS  Google Scholar 

  4. Ureshino H, Shindo T, Kimura S (2020) Role of cancer immunology in chronic myelogenous leukemia. Leuk Res 88:106273

    Article  Google Scholar 

  5. Ureshino H, Shindo T, Tanaka H et al (2021) HLA polymorphisms are associated with treatment-free remission following discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia. Mol Cancer Ther 20:142–149

    Article  CAS  Google Scholar 

Download references

Funding

SK reports grants and personal fees from Bristol-Myers Squibb, Pfizer, and Novartis Pharmaceuticals outside the submitted work.

Author information

Authors and Affiliations

  1. Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan

    Hiroshi Ureshino, Kazuharu Kamachi & Shinya Kimura

  2. Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Takero Shindo

Authors
  1. Hiroshi Ureshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuharu Kamachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takero Shindo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shinya Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Ureshino.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical Approval

This study was approved by the institutional review board of Saga University (UMIN-CTR, ID: R000020356).

Informed Consent

Written informed consent was obtained from all patients before registration, as required by the Declaration of Helsinki.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ureshino, H., Kamachi, K., Shindo, T. et al. Favorable HLA Polymorphisms are Associated with Lower Molecular Relapse after Tyrosine Kinase Discontinuation in Patients with Chronic Myeloid Leukemia. Indian J Hematol Blood Transfus 38, 760–761 (2022). https://doi.org/10.1007/s12288-022-01538-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-022-01538-w

Search

Navigation